Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Reimbursement News » Confirmatory Testing, Insurance Coverage Growing Alongside DTC Genetic Testing

Confirmatory Testing, Insurance Coverage Growing Alongside DTC Genetic Testing

Mar 22, 2019
|
Turna Ray
Premium

This article has been updated to clarify the details of a study on confirmatory testing by Ambry Genetics.

NEW YORK (GenomeWeb) – Recognizing the growing popularity of direct-to-consumer (DTC) genetic testing services like 23andMe, clinical labs are being asked to verify results that indicate individuals have an increased risk for diseases like cancer, and some commercial insurers are even paying for this confirmatory testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

For Vaccine Variant Updates

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

Concerns Over Variant Found in California

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Global 'Force' to Track Viral Variants

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

PNAS Papers on Breast Cancer Immunotherapy, Histone Mutations, Mosquito Mapping

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

What's Popular?

In Molecular Diagnostics

  1. Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

  2. SARS-CoV-2 Test Pooling Studies Offer Insights for Implementing, Optimizing Approaches

  3. Adaptive Biotechnologies, LabCorp Expand Collaboration

  4. AnchorDx Closes $40M Series C Financing Round

  5. UPDATE: Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.